[go: up one dir, main page]

US20110071161A1 - Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof - Google Patents

Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof Download PDF

Info

Publication number
US20110071161A1
US20110071161A1 US12/956,764 US95676410A US2011071161A1 US 20110071161 A1 US20110071161 A1 US 20110071161A1 US 95676410 A US95676410 A US 95676410A US 2011071161 A1 US2011071161 A1 US 2011071161A1
Authority
US
United States
Prior art keywords
alkyl
cycloalkyl
group
hydrogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/956,764
Inventor
Christian Hoornaert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to US12/956,764 priority Critical patent/US20110071161A1/en
Publication of US20110071161A1 publication Critical patent/US20110071161A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms

Definitions

  • the present invention relates to triazolopyridine carboxamide derivatives, to the preparation thereof and to the therapeutic use thereof.
  • X is a hydrogen atom, a halogen atom, or a (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, S(O) m R′′, hydroxyl or cyano group,
  • A is absent or else is a bond, an oxygen atom, a sulfur atom, an NR, C(O)NR′ or SO 2 NR′ group, a (C 1 -C 2 )alkylene group or a (C 2 )alkenyl group,
  • R 1 and R 2 are, independently of one another, one or more groups selected from a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkoxy group, a (C 3 -C 7 )cycloalkyl group, a (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkyl group, a (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkoxy group, a halogen atom, a cyano group, a C(O)R′, C(O)OR′, C(O)NR 10 R 20 or NO 2 group, or an NR 10 R 20 or NR 10 C(O)—R 20 group, the (C 1 -C 6 )alkyl and (C 1 -C 6 )alkoxy groups being optionally substituted with one or more atoms or groups selected, independently of one another, from halogen atoms and
  • R is a group selected from a hydrogen atom, and a (C 1 -C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkyl, C(O)R′, SO 2 R′′, CO 2 R′′ or C(O)NR 10 R 20 group,
  • R′ is a group selected from a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 3 -C 7 )cycloalkyl group and a (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkyl group,
  • R′′ is a group selected from a (C 1 -C 6 )alkyl group, a (C 3 -C 7 )cycloalkyl group and a (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkyl group,
  • R 10 and R 20 are, independently of one another, one or more groups selected from a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 3 -C 7 )cycloalkyl group and a (C 3 -C 7 )cycloalkyl(C 1 -C 6 )alkyl group, or else R 10 and R 20 can form a saturated or partially unsaturated ring containing from 5 to 7 carbon atoms and optionally containing a heteroatom chosen from O, N or S(O) m ,
  • n 0, 1 or 2.
  • the compounds of formula (I) can contain one or more asymmetrical carbon atoms. They can therefore exist in the form of enantiomers or of diastereoisomers. These enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, are part of the invention.
  • the compounds of formula (I) can exist in the form of bases or of addition salts with acids. Such addition salts are part of the invention. These salts can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for purifying or isolating compounds of formula (I) are also part of the invention.
  • the compounds of formula (I) can also exist in the form of hydrates or of solvates, i.e. in the form of associations or of combinations with one or more molecules of water or with a solvent. Such hydrates and solvates are also part of the invention. In the context of the present invention:
  • X is a hydrogen or halogen atom
  • A is absent or else is a bond, an oxygen atom, a sulfur atom, an NR, C(O)NR′ or SO 2 NR′ group, a (C 1 -C 2 )alkylene group or a (C 2 )alkenyl group.
  • a second group of compounds comprises the compounds of formula (I) for which:
  • X is a hydrogen or halogen atom
  • A is absent or else is a bond or a (C 1 -C 2 )alkylene group
  • R 1 and R 2 are, independently of one another, one or more groups selected from a hydrogen atom, a halogen atom, a cyano group or an alkoxy group.
  • a third group of compounds comprises the compounds of formula (I) for which:
  • X is a hydrogen or halogen atom
  • A is absent or else is a bond or an ethylene group
  • R 1 and R 2 are, independently of one another, one or more groups selected from a hydrogen or halogen atom.
  • a fourth group of compounds comprises the compounds of formula (I) for which:
  • X is a hydrogen or chlorine atom
  • A is absent or else is a bond or an ethylene group
  • R 1 and R 2 are, independently of one another, one or more groups selected from a hydrogen atom, a fluorine atom or a chlorine atom.
  • a first method (scheme 1) consists in reacting a triazolopyridine derivative of formula (II) in which X is as defined above, with a carbamoyl chloride of formula (III) in which R 1 , R 2 and A are as defined above, in a solvent such as tetrahydrofuran, in the presence of a base such as diisopropylethylamine and of a catalyst such as 4-dimethylaminopyridine.
  • a second method (scheme 2) consists in reacting a triazolopyridine derivative of formula (IV) in which X is as defined above, with a derivative of formula (V) in which R 1 , R 2 and A are as defined above and L is a leaving group, in a solvent such as acetonitrile and in the presence of a base such as diisopropylethylamine.
  • 0.62 ml (3.75 mmol) of diisopropylethylamine is added to a suspension of 0.865 g (2.75 mmol) of 4-benzhydrylpiperazine-1-carbonyl chloride obtained in step 1.1., of 0.300 g (2.50 mmol) of 1H-[1.2.3]triazolo[4.5-b]pyridine and of 0.015 g (0.12 mmol) of 4-dimethylaminopyridine in 5 ml of tetrahydrofuran.
  • the mixture is stirred at ambient temperature for 4 hours and then 60 ml of ethyl acetate and 15 ml of water are added.
  • the organic phase is separated by settling out and washed with 2 ⁇ 15 ml of water and then 15 ml of a saturated aqueous solution of sodium chloride.
  • the product is dried over sodium sulfate and evaporated under vacuum.
  • the product is purified by silica gel chromatography, elution being carried out with a 25:75, then 30:70, 35:65 and 40:60 mixtures of ethyl acetate and cyclohexane.
  • the product is subsequently recrystallized from isopropanol, so as to obtain 0.63 g (1.58 mmol) of product in the form of white crystals.
  • Example 2 The process is carried out according to Example 1, using 0.757 g (2.16 mmol) of 4-[bis(4-fluorophenyl)methyl]piperazine-1-carbonyl chloride (obtained according to Example 1.1) and 0.216 g (1.80 mmol) of 1H-[1,2,3]triazolo[4,5-b]pyridine.
  • the product is recrystallized from isopropanol, so as to obtain 0.50 g (1.15 mmol) of product in the form of white crystals.
  • Example 2 The process is carried out according to Example 1, using 0.882 g (2.30 mmol) of 4-[bis(4-chlorophenyl)methyl]piperazine-1-carbonyl chloride (obtained according to Example 1.1) and 0.240 g (2 mmol) of 1H-[1,2,3]triazolo[4,5-b]pyridine.
  • the product is recrystallized from a mixture of 2-butanone and diisopropyl ether, so as to obtain 0.57 g (1.22 mmol) of product in the form of white crystals.
  • Example 2 The process is carried out according to Example 1, using 0.757 g (2.16 mmol) of 4-[bis(4-fluorophenyl)methyl]piperazine-1-carbonyl chloride and 0.278 g (1.80 mmol) of 6-chloro-1H-[1,2,3]triazolo[4,5-b]pyridine.
  • the product is recrystallized from isopropanol, so as to obtain 0.60 g (1.28 mmol) of product in the form of white crystals.
  • the process is carried out according to Example 1, using 0.926 g (2.41 mmol) of 4-[bis(4-chlorophenyl)methyl]piperazine-1-carbonyl chloride and 0.324 g (2.10 mmol) of 6-chloro-1H-[1,2,3]triazolo[4,5-b]pyridine.
  • the product is recrystallized from a mixture of 2-butanone and diisopropyl ether, so as to obtain 0.71 g (1.41 mmol) of product in the form of white crystals.
  • Example 2 The process is carried out according to Example 1, using 0.790 g (2.32 mmol) of 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine-1-carbonyl chloride (obtained according to Example 1.1) and 0.278 g (2.32 mmol) of 1H-[1,2,3]triazolo[4,5-b]pyridine.
  • the product is recrystallized from ethyl acetate, so as to obtain 0.26 g (0.61 mmol) of product in the form of white crystals.
  • the organic phase is separated by settling out and is then washed with 3 ⁇ 20 ml of water and 20 ml of a saturated aqueous solution of sodium chloride.
  • the product is dried over sodium sulfate and evaporated to dryness.
  • the residue is recrystallized from isopropanol, so as to obtain 1.70 g (5.1 mmol) of product in the form of white crystals.
  • the solid form is filtered off and is washed with 3 ml of dichloromethane and with 2 ⁇ 6 ml of diisopropyl ether, and then dried under vacuum in the presence of phosphorus pentoxide, so as to obtain 0.46 g (1.5 mmol) of product in the form of white powder.
  • the mixture is separated by settling out and the organic phase is washed with 2 ⁇ 10 ml of water and then with 10 ml of a saturated aqueous solution of sodium chloride.
  • the product is dried over sodium sulfate and evaporated under vacuum.
  • the product is purified by silica gel chromatography, elution being carried out with a 40:60 then 50:50 mixture of ethyl acetate and cyclohexane, and then recrystallized from isopropanol, so as to obtain 0.40 g (1.01 mol) of product in the form of white crystals.
  • the compounds according to the invention surprisingly exhibit an inhibitory effect on the MGL (monoacyl glycerol lipase) enzyme.
  • the MGL enzyme catalyses the hydrolysis of endogenous derivatives of monoglyceride esters of various fatty acids (FEBS Letters 1998, 429, 152-156) and in particular the hydrolysis of 2-arachidonoylglycerol (2-AG) and of 1(3)-arachidonoylglycerol (1(3)-AG) (J. Biol. Chem. 1987, 272 (48), 27218-27223; Proc. Natl. Acad. Sci. USA 2002, 99 (16), 10819-10824; Biochem. Pharmacol. 2004, 67, 1381-1387; Mol. Pharmacol.
  • the 2-AG and 1-(3)-AG derivatives in particular interact with cannabinoid receptors (J. Biol. Chem. 1999, 274 (5), 2794-2801; J. Biol. Chem. 2000, 275 (1), 605-612; British J. Pharmacol. 2001, 134, 664-672).
  • the compounds of the invention block this degradation pathway and increase the tissue levels of these derivatives, and in particular of 2-AG and/or of 1(3)-AG.
  • they can be used in the prevention and treatment of pathologies in which 2-AG and/or 1(3)-AG, in particular, and/or any other substrate metabolized by the MGL enzyme, are involved (Progress Lipid Research 2006, 45, 405-446).
  • the compounds according to the invention have been the subject of pharmacological tests for determining their inhibitory effect on the MGL enzyme.
  • Tests comprised measuring the activity, in vitro, of the compounds of the invention on the MGL enzyme.
  • the inhibitory activity with respect to MGL is given by the concentration which inhibits 50% of the activity of MGL.
  • the inhibitory activity was measured in a radioenzymatic assay based on measuring the product of hydrolysis of 2-oleoyl glycerol ([ 3 H] 2-OG) by MGL.
  • the products of hydrolysis of [ 3 H] 2-OG, labeled on the glycerol, are oleic acid and [ 3 H]glycerol, and the source of MGL enzyme is a homogenate of mouse brain from which the cerebellum and the medulla oblongata have been removed.
  • the mouse brains are removed, and stored at ⁇ 80° C.
  • the dilution series of the compounds is prepared from stock solutions at 20 mM in 100% DMSO.
  • the first dilution of this series is prepared in 100% DMSO, then the second is prepared in the enzymatic reaction buffer (50 mM phosphate, 0.1% BSA) leading to the preparation of a 10-times concentrated concentration range.
  • the test compounds are preincubated at the selected concentration for 20 minutes with the mouse brain homogenate preparation.
  • the final concentration of DMSO in the enzymatic reaction does not exceed 0.1%.
  • Assaying of the MGL activity is carried out in a 96-well microplate in a final reaction volume of 100 ⁇ l. Briefly, 75 ⁇ g of proteins, preincubated with the test compounds, are diluted in 50 mM of phosphate buffer containing 0.1% of BSA and incubated, for 20 minutes at ambient temperature, in the presence of 50 ⁇ M of 2-OG containing an amount of [ 3 H] 2-OG of 0.027 ⁇ Ci/well (specific activity of 20 Ci/mmol). The reaction is stopped and the products formed are separated by adding and mixing 100 ⁇ l of chloroform/methanol (1/1).
  • the microplate After stirring for 10 minutes, the microplate is centrifuged for 15 minutes at 4000 g and a 30 ⁇ l aliquot of the aqueous phase containing the [ 3 H]glycerol produced is removed and then counted for 5 minutes by liquid scintillation (Wallac 1450 Microbeta).
  • the most active compounds of the invention have an IC 50 (concentration which inhibits 50% of the control enzymatic activity of MGL) of between 0.001 and 0.1 ⁇ M.
  • a subject of the invention is medicaments which comprise a compound of formula (I), or an addition salt of the latter with a pharmaceutically acceptable acid, or else a hydrate or a solvate of the compound of formula (I).
  • medicaments find use in therapeutics, in particular in the treatment and prevention of:
  • the present invention also relates to a method for treating the pathological conditions indicated above, which comprises the administration of an effective dose of a compound according to the invention, or a pharmaceutically acceptable salt or hydrate or solvate thereof, to a patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)

Abstract

The invention relates to the triazolopyridine carboxamide derivatives of general formula (I):
Figure US20110071161A1-20110324-C00001
Wherein X, A, R1 and R2 are as defined herein. The invention further relates to preparation methods and therapeutic use thereof.

Description

  • This application is a continuation of U.S. application Ser. No. 12/573,961, filed Oct. 6, 2009, now allowed, which is a continuation of International Application No. PCT/FR2008/000535, filed Apr. 16, 2008, which are incorporated herein by reference in their entirety; and claims the benefit of priority of French Patent Application No. 0702807, filed Apr. 18, 2007.
  • The present invention relates to triazolopyridine carboxamide derivatives, to the preparation thereof and to the therapeutic use thereof.
  • The subject of the present invention is the compounds corresponding to formula (I)
  • Figure US20110071161A1-20110324-C00002
  • in which:
  • X is a hydrogen atom, a halogen atom, or a (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, S(O)mR″, hydroxyl or cyano group,
  • A is absent or else is a bond, an oxygen atom, a sulfur atom, an NR, C(O)NR′ or SO2NR′ group, a (C1-C2)alkylene group or a (C2)alkenyl group,
  • R1 and R2 are, independently of one another, one or more groups selected from a hydrogen atom, a (C1-C6)alkyl group, a (C1-C6)alkoxy group, a (C3-C7)cycloalkyl group, a (C3-C7)cycloalkyl(C1-C6)alkyl group, a (C3-C7)cycloalkyl(C1-C6)alkoxy group, a halogen atom, a cyano group, a C(O)R′, C(O)OR′, C(O)NR10R20 or NO2 group, or an NR10R20 or NR10C(O)—R20 group, the (C1-C6)alkyl and (C1-C6)alkoxy groups being optionally substituted with one or more atoms or groups selected, independently of one another, from halogen atoms and hydroxyl, amino or NR10R20 groups,
  • R is a group selected from a hydrogen atom, and a (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, C(O)R′, SO2R″, CO2R″ or C(O)NR10R20 group,
  • R′ is a group selected from a hydrogen atom, a (C1-C6)alkyl group, a (C3-C7)cycloalkyl group and a (C3-C7)cycloalkyl(C1-C6)alkyl group,
  • R″ is a group selected from a (C1-C6)alkyl group, a (C3-C7)cycloalkyl group and a (C3-C7)cycloalkyl(C1-C6)alkyl group,
  • R10 and R20 are, independently of one another, one or more groups selected from a hydrogen atom, a (C1-C6)alkyl group, a (C3-C7)cycloalkyl group and a (C3-C7)cycloalkyl(C1-C6)alkyl group, or else R10 and R20 can form a saturated or partially unsaturated ring containing from 5 to 7 carbon atoms and optionally containing a heteroatom chosen from O, N or S(O)m,
  • m represents 0, 1 or 2.
  • The compounds of formula (I) can contain one or more asymmetrical carbon atoms. They can therefore exist in the form of enantiomers or of diastereoisomers. These enantiomers and diastereoisomers, and also mixtures thereof, including racemic mixtures, are part of the invention.
    The compounds of formula (I) can exist in the form of bases or of addition salts with acids. Such addition salts are part of the invention.
    These salts can be prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for purifying or isolating compounds of formula (I) are also part of the invention.
    The compounds of formula (I) can also exist in the form of hydrates or of solvates, i.e. in the form of associations or of combinations with one or more molecules of water or with a solvent. Such hydrates and solvates are also part of the invention.
    In the context of the present invention:
      • Ct-z, where t and z can take the values of 1 to 7, is intended to mean a carbon chain or ring that can have from t to z carbon atoms; for example, C1-3 can characterize a carbon chain containing from 1 to 3 carbon atoms;
      • a halogen atom is intended to mean: a fluorine, a chlorine, a bromine or an iodine;
      • an alkyl group is intended to mean: a linear or branched, saturated aliphatic group. By way of examples, mention may be made of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, etc, groups;
      • a cycloalkyl group is intended to mean: a saturated cyclic aliphatic group. By way of examples, mention may be made of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc, groups;
      • an alkylene group is intended to mean: a linear or branched, saturated divalent aliphatic group. By way of example, a C1-3-alkylene group is a linear or branched, divalent carbon chain containing from 1 to 3 carbon atoms, such as a methylenyl (—CH2—), an ethylenyl (—CH2CH2—), a 1-methylethylenyl (—CH(CH3)CH2—), a propylenyl (—CH2CH2CH2—), etc;
      • an alkenyl group is intended to mean: a linear or branched, monounsaturated or polyunsaturated aliphatic group comprising, for example, one or two ethylenic unsaturations; by way of example, a (C2)alkenyl group is a carbon chain containing 2 carbon atoms and one ethylenic unsaturation, such as an ethenyl (—CH═CH—);
      • an alkoxy group is intended to mean: an —O-alkyl radical where the alkyl group is as defined above;
      • a haloalkyl group is intended to mean: an alkyl group in which one or more hydrogen atoms have been substituted with a halogen atom. By way of examples, mention may be made of —CF3 and —CH2CF3 groups;
      • the sulfur atoms may be present in the oxidized state (sulfoxide, sulfone).
        In the various groups as defined below, the groups R1, R2, R and R′, when they are not defined, have the same meanings as those mentioned above.
        Among the compounds of formula (I) which are subjects of the invention, a first group of compounds comprises the compounds for which:
  • X is a hydrogen or halogen atom,
  • A is absent or else is a bond, an oxygen atom, a sulfur atom, an NR, C(O)NR′ or SO2NR′ group, a (C1-C2)alkylene group or a (C2)alkenyl group.
  • Among the compounds of formula (I) which are subjects of the invention, a second group of compounds comprises the compounds of formula (I) for which:
  • X is a hydrogen or halogen atom,
  • A is absent or else is a bond or a (C1-C2)alkylene group,
  • R1 and R2 are, independently of one another, one or more groups selected from a hydrogen atom, a halogen atom, a cyano group or an alkoxy group.
  • Among the compounds of formula (I) which are subjects of the invention, a third group of compounds comprises the compounds of formula (I) for which:
  • X is a hydrogen or halogen atom,
  • A is absent or else is a bond or an ethylene group,
  • R1 and R2 are, independently of one another, one or more groups selected from a hydrogen or halogen atom.
  • Among the compounds of formula (I) which are subjects of the invention, a fourth group of compounds comprises the compounds of formula (I) for which:
  • X is a hydrogen or chlorine atom,
  • A is absent or else is a bond or an ethylene group,
  • R1 and R2 are, independently of one another, one or more groups selected from a hydrogen atom, a fluorine atom or a chlorine atom.
  • The combinations of groups one to four as defined above are also part of the invention.
    Among the compounds of formula (I) which are subjects of the invention, mention may in particular be made of the following compounds:
    • (4-benzhydrylpiperazin-1-yl)[1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone;
    • (4-benzhydrylpiperazin-1-yl)(6-chloro[1,2,3]triazolo[4,5-b]pyridin-1-yl)methanone;
    • {-4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}[1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone;
    • {-4-[bis(4-chlorophenyl)methyl]piperazin-1-yl}[1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone;
    • {4-[bis(4-fluorophenyl)methyl]piperazin-1-yl}(6-chloro[1,2,3]triazolo[4,5-b]pyridin-1-yl)-methanone;
    • {-4-[bis(4-chlorophenyl)methyl]piperazin-1-yl}(6-chloro[1,2,3]triazolo[4,5-b]pyridin-1-yl)-methanone;
    • [4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl][1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone;
    • [4-(9H-fluoren-9-yl)piperazin-1-yl][1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone.
      In the subsequent text, the term “protective group Pg” is intended to mean a group which makes it possible, firstly, to protect a reactive function such as a hydroxyl or amine during a synthesis and, secondly, to regenerate the intact reactive function at the end of synthesis. Examples of protective groups and also protection and deprotection methods are given in “Protective Groups in Organic Synthesis”, Greene et al., 2nd Edition (John Wiley & Sons, Inc., New York), 1991.
      In the subsequent text, the term “leaving group” is intended to mean a group that can be readily cleaved from a molecule by breaking a heterolytic bond, with the departure of a pair of electrons. This group can thus be readily replaced with another group during a substitution reaction, for example. Such leaving groups are, for example, halogens or an activated hydroxyl group such as a methanesulfonate, benzenesulfonate, p-toluenesulfonate, triflate, acetate, etc. Examples of leaving groups and also references for the preparation thereof are given in “Advances in Organic Chemistry”, J. March, 3rd Edition, Wiley Interscience, 1985, p. 310-316.
      In accordance with the invention, the compounds of formula (I) can be prepared according to the process which follows.
  • A first method (scheme 1) consists in reacting a triazolopyridine derivative of formula (II) in which X is as defined above, with a carbamoyl chloride of formula (III) in which R1, R2 and A are as defined above, in a solvent such as tetrahydrofuran, in the presence of a base such as diisopropylethylamine and of a catalyst such as 4-dimethylaminopyridine.
  • Figure US20110071161A1-20110324-C00003
  • A second method (scheme 2) consists in reacting a triazolopyridine derivative of formula (IV) in which X is as defined above, with a derivative of formula (V) in which R1, R2 and A are as defined above and L is a leaving group, in a solvent such as acetonitrile and in the presence of a base such as diisopropylethylamine.
  • Figure US20110071161A1-20110324-C00004
  • The compounds of formulae (II), (III), (IV) and (V), when the method for preparing them is not described above, are commercially available or described in the literature, or else can be prepared according to methods which are described therein or which are known to those skilled in the art.
    According to another of its aspects, a subject of the invention is also the compounds of formula (IV), in which X is as defined above, in their base or salt form. These compounds are of use as intermediates for the synthesis of the compounds of formula (I). The examples which follow illustrate the preparation of some compounds of the invention.
    These examples are not limiting and merely illustrate the invention. The microanalyses, the IR and NMR spectra and/or the LC-MS analyses confirm the structures and the purities of the compounds obtained. The numbers of the compounds exemplified refer to those given in the table hereinafter, which illustrates the chemical structures and the physical properties of some compounds according to the invention.
    • EXAMPLE 1 (4-Benzhydrylpiperazin-1-yl)[1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone 1.1. 4-Benzhydrylpiperazine-1-carbonyl chloride
  • A solution of 2.522 g (10 mmol) of 1-benzhydrylpiperazine and of 1.62 ml (20 mmol) of pyridine in 15 ml of dichloromethane is added, dropwise, to a solution of 1.187 g (4 mmol) of triphosgene in 10 ml of dichloromethane, cooled to −5° C. under an argon atmosphere. Stirring is continued at −5° C. for 15 minutes and then at ambient temperature for 3 hours. 50 ml of dichloromethane and 50 ml of water are subsequently added. The mixture is separated by settling out and the organic phase is washed with 2×25 ml of water and then 25 ml of a saturated aqueous solution of sodium chloride. The product is dried over sodium sulfate and evaporated under vacuum, so as to obtain 2.72 g of product in the form of a gum, used as it is in the following step.
    • 1.2. (4-Benzhydrylpiperazin-1-yl)[1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone
  • 0.62 ml (3.75 mmol) of diisopropylethylamine is added to a suspension of 0.865 g (2.75 mmol) of 4-benzhydrylpiperazine-1-carbonyl chloride obtained in step 1.1., of 0.300 g (2.50 mmol) of 1H-[1.2.3]triazolo[4.5-b]pyridine and of 0.015 g (0.12 mmol) of 4-dimethylaminopyridine in 5 ml of tetrahydrofuran. The mixture is stirred at ambient temperature for 4 hours and then 60 ml of ethyl acetate and 15 ml of water are added. The organic phase is separated by settling out and washed with 2×15 ml of water and then 15 ml of a saturated aqueous solution of sodium chloride. The product is dried over sodium sulfate and evaporated under vacuum. The product is purified by silica gel chromatography, elution being carried out with a 25:75, then 30:70, 35:65 and 40:60 mixtures of ethyl acetate and cyclohexane. The product is subsequently recrystallized from isopropanol, so as to obtain 0.63 g (1.58 mmol) of product in the form of white crystals.
  • Melting point (° C.): 146-148 (decomposition)
  • LC-MS (m/z): 399 (MH+)
  • IR (KBr, cm−1): 1697
  • 1H-NMR (CDCl3, δ ppm): 8.80 (dd, 1H), 8.40 (dd, 1H), 7.55 (dd, 1H), 7.45-7.15 (m, 10H), 4.35 (s, 1H), 4.00 (m, 4H), 2.60 (m, 4H).
    • EXAMPLE 2 (4-Benzhydrylpiperazin-1-yl)(6-chloro[1,2,3]triazolo[4,5-b]pyridin-1-yl)methanone
  • The process is carried out as described in Example 1, using 0.651 g (2.07 mmol) of 4-benzhydrylpiperazine-1-carbonyl chloride and 0.278 g (1.80 mmol) of 6-chloro-1H-[1,2,3]triazolo[4,5-b]pyridine (J. Am. Chem. Soc. 1949, 1885). The product is recrystallized from a mixture of 2-butanone and diisopropyl ether, so as to obtain 0.46 g (1.06 mmol) of product in the form of white crystals.
  • Melting point (° C.): 173-175 (decomposition)
  • LC-MS (m/z): 455 (MNa+), 471 (MK+)
  • IR (KBr, cm−1): 1706
  • 1H-NMR (CDCl3, δ ppm): 8.75 (s, 1H), 8.30 (s, 1H), 7.45 (m, 4H), 7.35-7.20 (m, 6H), 4.35 (s, 1H), 4.00 (m, 4H), 2.65 (m, 4H).
    • EXAMPLE 3 {4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl}[1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone
  • The process is carried out according to Example 1, using 0.757 g (2.16 mmol) of 4-[bis(4-fluorophenyl)methyl]piperazine-1-carbonyl chloride (obtained according to Example 1.1) and 0.216 g (1.80 mmol) of 1H-[1,2,3]triazolo[4,5-b]pyridine. The product is recrystallized from isopropanol, so as to obtain 0.50 g (1.15 mmol) of product in the form of white crystals.
  • Melting point (° C.): 151-153 (decomposition)
  • LC-MS (m/z): 435 (MH+)
  • IR (KBr, cm−1): 1712
  • 1H-NMR (CDCl3, δ ppm): 8.85 (d, 1H), 8.40 (d, 1H), 7.55 (dd, 1H), 7.40 (m, 4H), 7.05 (m, 4H), 4.40 (s, 1H), 4.00 (m, 4H), 2.60 (m, 4H).
    • EXAMPLE 4 {4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl}[1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone
  • The process is carried out according to Example 1, using 0.882 g (2.30 mmol) of 4-[bis(4-chlorophenyl)methyl]piperazine-1-carbonyl chloride (obtained according to Example 1.1) and 0.240 g (2 mmol) of 1H-[1,2,3]triazolo[4,5-b]pyridine. The product is recrystallized from a mixture of 2-butanone and diisopropyl ether, so as to obtain 0.57 g (1.22 mmol) of product in the form of white crystals.
  • Melting point (° C.): 163-165 (decomposition)
  • LC-MS (m/z): 467 (MH+)
  • IR (KBr, cm−1): 1715
  • 1H-NMR (CDCl3, δ ppm): 8.70 (d, 1H), 8.30 (d, 1H), 7.45 (dd, 1H), 7.30-7.15 (m, 8H), 4.25 (s, 1H), 3.90 (m, 4H), 2.50 (m, 4H).
    • EXAMPLE 5 {4-[Bis(4-fluorophenyl)methyl]piperazin-1-yl}(6-chloro[1,2,3]triazolo[4,5-b]pyridin-1-yl)-methanone
  • The process is carried out according to Example 1, using 0.757 g (2.16 mmol) of 4-[bis(4-fluorophenyl)methyl]piperazine-1-carbonyl chloride and 0.278 g (1.80 mmol) of 6-chloro-1H-[1,2,3]triazolo[4,5-b]pyridine. The product is recrystallized from isopropanol, so as to obtain 0.60 g (1.28 mmol) of product in the form of white crystals.
  • Melting point (° C.): 167-169 (decomposition)
  • LC-MS (m/z): 469 (MH+)
  • IR (KBr, cm−1): 1704
  • 1H-NMR (CDCl3, δ ppm): 8.75 (s, 1H), 8.40 (s, 1H), 7.40 (m, 4H), 7.05 (m, 4H), 4.35 (s, 1H), 4.00 (m, 4H), 2.60 (m, 4H).
    • EXAMPLE 6 {4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl}(6-chloro[1,2,3]triazolo[4,5-b]pyridin-1-yl)-methanone
  • The process is carried out according to Example 1, using 0.926 g (2.41 mmol) of 4-[bis(4-chlorophenyl)methyl]piperazine-1-carbonyl chloride and 0.324 g (2.10 mmol) of 6-chloro-1H-[1,2,3]triazolo[4,5-b]pyridine. The product is recrystallized from a mixture of 2-butanone and diisopropyl ether, so as to obtain 0.71 g (1.41 mmol) of product in the form of white crystals.
  • Melting point (° C.): 172-174 (decomposition)
  • IR (KBr, cm−1): 1702
  • 1H-NMR (d6-DMSO, δ ppm): 8.85 (s, 1H), 8.50 (s, 1H), 7.45 (d, 4H), 7.40 (d, 4H), 4.55 (s, 1H), 3.80 (m, 4H), 2.45 (m, 4H).
    • EXAMPLE 7 [4-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazin-1-yl][1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone
  • The process is carried out according to Example 1, using 0.790 g (2.32 mmol) of 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)piperazine-1-carbonyl chloride (obtained according to Example 1.1) and 0.278 g (2.32 mmol) of 1H-[1,2,3]triazolo[4,5-b]pyridine. The product is recrystallized from ethyl acetate, so as to obtain 0.26 g (0.61 mmol) of product in the form of white crystals.
  • Melting point (° C.): 190-194 (decomposition)
  • LC-MS (m/z): 447 (MNa+), 463 (MK+), 871 (MMNa+)
  • IR (KBr, cm−1): 1707
  • 1H-NMR (CDCl3, δ ppm): 8.80 (d, 1H), 8.35 (d, 1H), 7.55 (dd, 1H), 7.25-7.05 (m, 8H), 4.15-3.85 (m, 7H), 2.95-2.80 (m, 2H), 2.55 (m, 4H).
    • EXAMPLE 8 [4-(9H-Fluoren-9-yl)piperazin-1-yl][1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone 8.1. tert-Butyl 4-([1,2,3]triazolo[4,5-b]pyridine-1-carbonyl)piperazine-1-carboxylate
  • 1.39 ml (8.40 mmol) of diisopropylethylamine are added to a suspension of 0.840 g (7 mmol) of 1H-[1,2,3]triazolo[4,5-b]pyridine, of 1.741 g (7 mmol) of tert-butyl 4-chlorocarbonylpiperazine-1-carboxylate (Bioorg. Med. Chem. Lett. 2000, 10, 2357) and of 0.042 g (0.35 mmol) of 4-dimethylaminopyridine in 14 ml of tetrahydrofuran. The mixture is stirred at ambient temperature for 4 hours and then 80 ml of ethyl acetate and 20 ml of water are added. The organic phase is separated by settling out and is then washed with 3×20 ml of water and 20 ml of a saturated aqueous solution of sodium chloride. The product is dried over sodium sulfate and evaporated to dryness. The residue is recrystallized from isopropanol, so as to obtain 1.70 g (5.1 mmol) of product in the form of white crystals.
  • Melting point (° C.): 155-157 (decomposition)
    • 8.2. piperazin-1-yl[1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone dihydrochloride
  • 1.8 ml of a 5N solution of hydrochloric acid (9 mmol) in isopropanol are added to a solution of 0.498 g (1.50 mmol) of tert-butyl 4-([1,2,3]triazolo[4,5-b]pyridine-1-carbonyl)piperazine-1-carboxylate prepared in step 8.1., in 7.5 ml of dichloromethane. Stirring is continued overnight at ambient temperature. The solid form is filtered off and is washed with 3 ml of dichloromethane and with 2×6 ml of diisopropyl ether, and then dried under vacuum in the presence of phosphorus pentoxide, so as to obtain 0.46 g (1.5 mmol) of product in the form of white powder.
  • Melting point (° C.): 160 (decomposition)
  • LC-MS (m/z): 233 (MH+)
  • IR (KBr, cm−1): 1714
  • 1H-NMR (d6-DMSO, δ ppm): 9.60 (m, 2H), 8.80 (d, 1H), 8.40 (d, 1H), 7.75 (dd, 1H), 4.05 (m, 4H), 3.25 (m, 4H)
    • 8.3. [4-(9H-Fluoren-9-yl)piperazin-1-yl][1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone
  • 0.83 ml (5 mmol) of diisopropylethylamine is added to a suspension of 0.381 g (1.25 mmol) of piperazin-1-yl[1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone dihydrochloride, prepared in step 8.2., and of 0.337 g (1.38 mmol) of 9-bromo-9H-fluorene in 4 ml of acetonitrile. The solution is stirred overnight at ambient temperature and is then evaporated. The residue is taken up in a mixture of 40 ml of ethyl acetate and 10 ml of water. The mixture is separated by settling out and the organic phase is washed with 2×10 ml of water and then with 10 ml of a saturated aqueous solution of sodium chloride. The product is dried over sodium sulfate and evaporated under vacuum. The product is purified by silica gel chromatography, elution being carried out with a 40:60 then 50:50 mixture of ethyl acetate and cyclohexane, and then recrystallized from isopropanol, so as to obtain 0.40 g (1.01 mol) of product in the form of white crystals.
  • Melting point (° C.): 170-172 (decomposition)
  • LC-MS (m/z): 397 (MH+), 815 (MMNa+)
  • IR (KBr, cm−1): 1723
  • 1H-NMR (CDCl3, δ ppm): 8.80 (dd, 1H), 8.35 (dd, 1H), 7.75-7.65 (m, 4H), 7.55 (dd, 1H), 7.45-7.25 (m, 4H), 4.95 (s, 1H), 3.95 (m, 4H), 2.85 (m, 4H).
  • The table which follows illustrates the chemical structures and the physical properties of some examples of compounds according to the invention. In this table:
      • Mp (° C.) is the melting point of the compound in degrees Celsius;
      • in column “A”, “−” signifies that A is absent;
      • in the “salt” column, “−” represents a compound in the form of a free base, whereas “HCl” represents a compound in hydrochloride form.
        The compounds described in this table were prepared according to the methods described above.
  • TABLE 1
    (I)
    Figure US20110071161A1-20110324-C00005
    No. X A R1 R2 Salt Mp (° C.)
    1 H — H H — 146-148
    2 Cl — H H — 173-175
    3 H — 4-F 4-F — 151-153
    4 H — 4-Cl 4-Cl — 163-165
    5 Cl — 4-F 4-F — 167-169
    6 Cl — 4-Cl 4-Cl — 172-174
    7 H —CH2CH2— H H — 190-194
    8 H bond H H — 170-172
  • The compounds according to the invention surprisingly exhibit an inhibitory effect on the MGL (monoacyl glycerol lipase) enzyme. The MGL enzyme catalyses the hydrolysis of endogenous derivatives of monoglyceride esters of various fatty acids (FEBS Letters 1998, 429, 152-156) and in particular the hydrolysis of 2-arachidonoylglycerol (2-AG) and of 1(3)-arachidonoylglycerol (1(3)-AG) (J. Biol. Chem. 1987, 272 (48), 27218-27223; Proc. Natl. Acad. Sci. USA 2002, 99 (16), 10819-10824; Biochem. Pharmacol. 2004, 67, 1381-1387; Mol. Pharmacol. 2004, 66 (5), 1260-1264). The 2-AG and 1-(3)-AG derivatives in particular interact with cannabinoid receptors (J. Biol. Chem. 1999, 274 (5), 2794-2801; J. Biol. Chem. 2000, 275 (1), 605-612; British J. Pharmacol. 2001, 134, 664-672).
  • The compounds of the invention block this degradation pathway and increase the tissue levels of these derivatives, and in particular of 2-AG and/or of 1(3)-AG. In this respect, they can be used in the prevention and treatment of pathologies in which 2-AG and/or 1(3)-AG, in particular, and/or any other substrate metabolized by the MGL enzyme, are involved (Progress Lipid Research 2006, 45, 405-446).
  • The compounds according to the invention have been the subject of pharmacological tests for determining their inhibitory effect on the MGL enzyme.
  • Tests comprised measuring the activity, in vitro, of the compounds of the invention on the MGL enzyme.
  • The inhibitory activity with respect to MGL is given by the concentration which inhibits 50% of the activity of MGL.
  • The inhibitory activity was measured in a radioenzymatic assay based on measuring the product of hydrolysis of 2-oleoyl glycerol ([3H] 2-OG) by MGL. The products of hydrolysis of [3H] 2-OG, labeled on the glycerol, are oleic acid and [3H]glycerol, and the source of MGL enzyme is a homogenate of mouse brain from which the cerebellum and the medulla oblongata have been removed. The mouse brains are removed, and stored at −80° C. until they are used or homogenized immediately for twice 5 seconds using a Precellys apparatus at 5000 rpm (Bertin) in a 10 mM tris-HCl, 150 mM NaCl, 1 mM EDTA buffer (pH 8) at 4° C. The concentration of the homogenates is then adjusted to 7.5 μg/μl.
  • The dilution series of the compounds is prepared from stock solutions at 20 mM in 100% DMSO. The first dilution of this series is prepared in 100% DMSO, then the second is prepared in the enzymatic reaction buffer (50 mM phosphate, 0.1% BSA) leading to the preparation of a 10-times concentrated concentration range. The test compounds are preincubated at the selected concentration for 20 minutes with the mouse brain homogenate preparation. The final concentration of DMSO in the enzymatic reaction does not exceed 0.1%.
  • Assaying of the MGL activity is carried out in a 96-well microplate in a final reaction volume of 100 μl. Briefly, 75 μg of proteins, preincubated with the test compounds, are diluted in 50 mM of phosphate buffer containing 0.1% of BSA and incubated, for 20 minutes at ambient temperature, in the presence of 50 μM of 2-OG containing an amount of [3H] 2-OG of 0.027 μCi/well (specific activity of 20 Ci/mmol). The reaction is stopped and the products formed are separated by adding and mixing 100 μl of chloroform/methanol (1/1). After stirring for 10 minutes, the microplate is centrifuged for 15 minutes at 4000 g and a 30 μl aliquot of the aqueous phase containing the [3H]glycerol produced is removed and then counted for 5 minutes by liquid scintillation (Wallac 1450 Microbeta).
  • Under these conditions, the most active compounds of the invention have an IC50 (concentration which inhibits 50% of the control enzymatic activity of MGL) of between 0.001 and 0.1 μM.
  • For example, compounds No. 1 and 7 showed an IC50 of 0.004 and 0.025 μM, respectively.
    It therefore appears that the compounds according to the invention have an inhibitory activity with respect to MGL.
    The compounds according to the invention can therefore be used for the preparation of medicaments, in particular of medicaments which inhibit the MGL enzyme.
    Thus, according to another of its aspects, a subject of the invention is medicaments which comprise a compound of formula (I), or an addition salt of the latter with a pharmaceutically acceptable acid, or else a hydrate or a solvate of the compound of formula (I).
    These medicaments find use in therapeutics, in particular in the treatment and prevention of:
      • pain, in particular acute or chronic pain of neurogenic type: migraine, neuropathic pain including forms associated with the herpes virus and with diabetes;
      • acute or chronic pain associated with inflammatory diseases: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome;
      • acute or chronic peripheral pain;
      • dizziness, vomiting, nausea, in particular subsequent to chemotherapy;
      • eating disorders, in particular anorexia and cachexia of various natures;
      • metabolic syndrome and its manifestations, including obesity;
      • dyslipidemia and manifestations thereof, including atherosclerosis and coronary diseases;
      • neurological and psychiatric pathological conditions; shaking, dyskinesia, dystonia, spasticity, obsessive-compulsive behavior, Tourette's syndrome, all forms of depression and anxiety of any nature and origin, mood disorders, psychoses;
      • acute and chronic neurodegenerative diseases: Parkinson's disease, Alzheimer's disease, senile dementia, Huntington's chorea, lesions associated with cerebral ischaemia and with cranium and medullary trauma, amyotrophic lateral sclerosis;
      • epilepsy;
      • sleep disorders including sleep apnea;
      • cardiovascular diseases, in particular hypertension, cardiac arrhythmias, arteriosclerosis, heart attack, cardiac ischaemia;
      • renal ischaemia;
      • cancers: benign skin tumors, brain tumors and papillomas, prostate tumors, brain tumors (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumors of embryonic origin, astrocytomas, astroblastomas, ependyomas, oligodendrogliomas, plexus tumors, neuroepitheliomas, epiphyseal tumors, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, schwannomas);
      • immune system disorders, in particular autoimmune diseases: psoriasis, lupus erythematosus, diseases of the connective tissue or collagen diseases, Sjögren's syndrome, ankylosing spondylarthritis, undifferentiated spondylarthritis, Behcet's disease, hemolytic autoimmune anemias, multiple sclerosis, amyotrophic lateral sclerosis, amyloses, transplant rejection, diseases affecting the plasmocytic line;
      • allergic diseases: immediate or delayed hypersensitivity, allergic rhinitis or conjunctivitis, contact dermatitis;
      • parasitic, viral or bacterial infectious diseases: AIDS, meningitis;
      • inflammatory diseases, in particular diseases of the joints: arthritis, rheumatoid arthritis, osteoarthritis, spondylitis, gout, vasculitis, Crohn's disease, irritable bowel syndrome;
      • osteoporosis;
      • ocular conditions: ocular hypertension, glaucoma;
      • pulmonary conditions: respiratory tract diseases, bronchospasms, coughing, asthma, chronic bronchitis, chronic respiratory tract obstruction, emphysemas;
      • gastrointestinal diseases: irritable bowel syndrome, intestinal inflammatory disorders, ulcers, diarrhea;
      • urinary incontinence and bladder inflammation.
        According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active ingredient, a compound according to the invention. These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, a hydrate or a solvate of said compound, and also at least one pharmaceutically acceptable excipient. Said excipients are selected according to the pharmaceutical form and the method of administration desired, from the usual excipients which are known to those skilled in the art.
        In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of formula (I) above, or a possible salt, solvate or hydrate thereof, can be administered in unit administration form, as a mixture with conventional pharmaceutical excipients, to animals and to human beings for the prophylaxis or treatment of the disorders or diseases above.
        Suitable unit administration forms comprise oral forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, and forms for administration by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms, and implants. For topical application, the compounds according to the invention can be used in creams, gels, ointments or lotions.
        By way of example, a unit administration form of a compound according to the invention in tablet form may comprise the following components:
  • Compound according to the invention 50.0 mg
    Mannitol 223.75 mg 
    Sodium croscarmellose  6.0 mg
    Maize starch 15.0 mg
    Hydroxypropylmethylcellulose 2.25 mg
    Magnesium stearate  3.0 mg

    According to another of its aspects, the present invention also relates to a method for treating the pathological conditions indicated above, which comprises the administration of an effective dose of a compound according to the invention, or a pharmaceutically acceptable salt or hydrate or solvate thereof, to a patient.

Claims (10)

1. A compound of the formula (I):
Figure US20110071161A1-20110324-C00006
in which:
X is hydrogen, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, S(O)mR″, hydroxyl or cyano;
A is oxygen, sulfur, NR, C(O)NR′ or SO2NR′;
R1 and R2 are, independently of one another, one or more groups selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C3-C7)cycloalkyl(C1-C6)alkoxy, halogen, cyano, C(O)R′, C(O)OR′, C(O)NR10R20, NO2, NR10R20 and NR10C(O)—R20 group, wherein (C1-C6)alkyl and (C1-C6)alkoxy are optionally substituted with one or more groups selected, independently of one another, from halogen, hydroxyl, amino and NR10R20;
R is selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, C(O)R′, SO2R″, CO2R″ and C(O)NR10R20;
R′ is selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl and (C3-C7)cycloalkyl(C1-C6)alkyl;
R″ is selected from (C1-C6)alkyl, (C3-C7)cycloalkyl and (C3-C7)cycloalkyl(C1-C6)alkyl; and
R10 and R20 are, independently of one another, selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl and (C3-C7)cycloalkyl(C1-C6)alkyl; or
R10 and R20 form a saturated or partially unsaturated ring containing from 5 to 7 carbon atoms and optionally containing a heteroatom chosen from O, N or S(O)m; wherein
m represents 0, 1 or 2; or
a salt thereof.
2. The compound of formula (I) according to claim 1, wherein:
X is hydrogen or halogen; or
a salt thereof.
3. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
4. A pharmaceutical composition comprising a compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.
5. A method of treating a pathological condition in a patient in which endogenous 2-arachidonoylglycerol (2-AG) and endogenous 1(3)-arachidonoylglycerol or any other substrate metabolized by the MGL enzyme are involved comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
Figure US20110071161A1-20110324-C00007
in which:
X is hydrogen, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, S(O)mR″, hydroxyl or cyano;
A is absent or else is a bond, oxygen, sulfur, NR, C(O)NR′ or SO2NR′, (C1-C2)alkylene or (C2)alkenyl group;
when A is absent the attachment is a benzhydryl group;
R1 and R2 are, independently of one another, one or more groups selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C3-C7)cycloalkyl(C1-C6)alkoxy, halogen, cyano, C(O)R′, C(O)OR′, C(O)NR10R20, NO2, NR10R20 and NR10C(O)—R20 group, wherein (C1-C6)alkyl and (C1-C6)alkoxy are optionally substituted with one or more groups selected, independently of one another, from halogen, hydroxyl, amino and NR10R20;
R is selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, C(O)R′, SO2R″, CO2R″ and C(O)NR10R20;
R′ is selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl and (C3-C7)cycloalkyl(C1-C6)alkyl;
R″ is selected from (C1-C6)alkyl, (C3-C7)cycloalkyl and (C3-C7)cycloalkyl(C1-C6)alkyl; and
R10 and R20 are, independently of one another, selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl and (C3-C7)cycloalkyl(C1-C6)alkyl; or
R10 and R20 form a saturated or partially unsaturated ring containing from 5 to 7 carbon atoms and optionally containing a heteroatom chosen from O, N or S(O)m; wherein
m represents 0, 1 or 2; or
or a pharmaceutically acceptable salt thereof.
6. A method of treating a disease selected from the group consisting of acute or chronic pain, an inflammatory disease, dizziness, vomiting, nausea, eating disorders, metabolic syndrome, dyslipidemia, epilepsy, a sleep disorder, osteoporosis, ocular condition, pulmonary condition, gastrointestinal disease, urinary incontinence and bladder inflammation, comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
Figure US20110071161A1-20110324-C00008
in which:
X is hydrogen, halogen, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, S(O)mR″, hydroxyl or cyano;
A is absent or else is a bond, oxygen, sulfur, NR, C(O)NR′ or SO2NR′, (C1-C2)alkylene or (C2)alkenyl group;
when A is absent the attachment is a benzhydryl group;
R1 and R2 are, independently of one another, one or more groups selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, (C3-C7)cycloalkyl(C1-C6)alkoxy, halogen, cyano, C(O)R′, C(O)OR′, C(O)NR10R20, NO2, NR10R20 and NR10C(O)—R20 group, wherein (C1-C6)alkyl and (C1-C6)alkoxy are optionally substituted with one or more groups selected, independently of one another, from halogen, hydroxyl, amino and NR10R20;
R is selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)cycloalkyl(C1-C6)alkyl, C(O)R′, SO2R″, CO2R″ and C(O)NR10R20;
R′ is selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl and (C3-C7)cycloalkyl(C1-C6)alkyl;
R″ is selected from (C1-C6)alkyl, (C3-C7)cycloalkyl and (C3-C7)cycloalkyl(C1-C6)alkyl; and
R10 and R20 are, independently of one another, selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl and (C3-C7)cycloalkyl(C1-C6)alkyl; or
R10 and R20 form a saturated or partially unsaturated ring containing from 5 to 7 carbon atoms and optionally containing a heteroatom chosen from O, N or S(O)m; wherein
m represents 0, 1 or 2; or
or a pharmaceutically acceptable salt thereof.
7. The method according to claim 6, wherein the disease is selected from the group consisting of acute or chronic pain and an inflammatory disease.
8. The method according to claim 6 wherein the disease is selected from the group consisting of dizziness, vomiting, nausea, eating disorders, metabolic syndrome and dyslipidemia.
9. The method according to claim 6 wherein the disease is selected from the group consisting of epilepsy and a sleep disorder.
10. The method according to claim 6 wherein the disease is selected from the group consisting of osteoporosis, ocular condition, pulmonary condition, gastrointestinal disease, urinary incontinence and bladder inflammation.
US12/956,764 2007-04-18 2010-11-30 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof Abandoned US20110071161A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/956,764 US20110071161A1 (en) 2007-04-18 2010-11-30 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0702807A FR2915197B1 (en) 2007-04-18 2007-04-18 TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF.
FR0702807 2007-04-18
PCT/FR2008/000535 WO2008145842A2 (en) 2007-04-18 2008-04-16 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
US12/573,961 US7868007B2 (en) 2007-04-18 2009-10-06 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
US12/956,764 US20110071161A1 (en) 2007-04-18 2010-11-30 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/573,961 Continuation US7868007B2 (en) 2007-04-18 2009-10-06 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof

Publications (1)

Publication Number Publication Date
US20110071161A1 true US20110071161A1 (en) 2011-03-24

Family

ID=38739381

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/573,961 Expired - Fee Related US7868007B2 (en) 2007-04-18 2009-10-06 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
US12/956,764 Abandoned US20110071161A1 (en) 2007-04-18 2010-11-30 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/573,961 Expired - Fee Related US7868007B2 (en) 2007-04-18 2009-10-06 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof

Country Status (26)

Country Link
US (2) US7868007B2 (en)
EP (1) EP2146991B1 (en)
JP (1) JP2010524907A (en)
KR (1) KR20090130060A (en)
CN (1) CN101657451A (en)
AR (1) AR066103A1 (en)
AT (1) ATE475661T1 (en)
AU (1) AU2008257323A1 (en)
BR (1) BRPI0810430A2 (en)
CA (1) CA2683933A1 (en)
CY (1) CY1111601T1 (en)
DE (1) DE602008001981D1 (en)
DK (1) DK2146991T3 (en)
ES (1) ES2348969T3 (en)
FR (1) FR2915197B1 (en)
HR (1) HRP20100573T1 (en)
IL (1) IL201416A0 (en)
MX (1) MX2009011215A (en)
PL (1) PL2146991T3 (en)
PT (1) PT2146991E (en)
RS (1) RS51462B (en)
RU (1) RU2009142430A (en)
SI (1) SI2146991T1 (en)
TW (1) TW200906401A (en)
UY (1) UY31036A1 (en)
WO (1) WO2008145842A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2373315A4 (en) * 2008-11-14 2012-06-27 Scripps Research Inst METHOD AND COMPOSITION RELATING TO TARGETING MONO-ACYLGLYCEROL LIPASE
CN105399731A (en) * 2008-12-24 2016-03-16 比亚尔-珀特拉和Ca股份公司 Pharmaceutical Compounds
WO2010124114A1 (en) 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US8450350B2 (en) * 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
BR112013005141A2 (en) * 2010-09-03 2016-05-10 Janssen Pharmaceutica Nv diazetidinyl diamide as monoacylglycerol lipase inhibitors
BR112013007287A2 (en) 2010-09-27 2016-06-14 Janssen Pharmaceutica Nv oxopiperazine azetidine amides and oxodiazepine azetine amides as monoacylglycerol lipase inhibitors
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
EP2630139A1 (en) 2010-10-22 2013-08-28 Janssen Pharmaceutica, N.V. Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
KR20210044217A (en) * 2018-08-13 2021-04-22 에프. 호프만-라 로슈 아게 Novel heterocyclic compounds as monoacylglycerol lipase inhibitors
PE20211089A1 (en) 2018-08-13 2021-06-14 Hoffmann La Roche NEW HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONACILGLICEROL LIPASE
CA3111309A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv MGL PET RADIOLABE LIGANDS
MX2024008337A (en) 2021-12-29 2024-07-30 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl).

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
DE10247680B4 (en) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh New bicyclic inhibitors of the hormone sensitive lipase
DE102004005172A1 (en) * 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazole derivatives as inhibitors of the hormone sensitive lipase
US7632837B2 (en) * 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
DE102005049954A1 (en) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridine derivatives as inhibitors of lipases and phospholipases

Also Published As

Publication number Publication date
PL2146991T3 (en) 2011-01-31
UY31036A1 (en) 2008-11-28
CY1111601T1 (en) 2015-10-07
CN101657451A (en) 2010-02-24
PT2146991E (en) 2010-10-04
ATE475661T1 (en) 2010-08-15
JP2010524907A (en) 2010-07-22
US7868007B2 (en) 2011-01-11
BRPI0810430A2 (en) 2014-10-14
AR066103A1 (en) 2009-07-22
AU2008257323A1 (en) 2008-12-04
DE602008001981D1 (en) 2010-09-09
WO2008145842A2 (en) 2008-12-04
RS51462B (en) 2011-04-30
EP2146991B1 (en) 2010-07-28
RU2009142430A (en) 2011-05-27
KR20090130060A (en) 2009-12-17
CA2683933A1 (en) 2008-12-04
HRP20100573T1 (en) 2010-11-30
FR2915197B1 (en) 2009-06-12
EP2146991A2 (en) 2010-01-27
US20100035893A1 (en) 2010-02-11
FR2915197A1 (en) 2008-10-24
ES2348969T3 (en) 2010-12-17
DK2146991T3 (en) 2010-11-22
WO2008145842A3 (en) 2009-01-22
TW200906401A (en) 2009-02-16
IL201416A0 (en) 2010-05-31
SI2146991T1 (en) 2010-11-30
MX2009011215A (en) 2009-11-02

Similar Documents

Publication Publication Date Title
US7868007B2 (en) Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
US8080547B2 (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
US7863279B2 (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
RU2376305C2 (en) Derivatives of aryl- and heteroarylpiperidinecarboxylates, their production and their use as inhibitors of faah ferment
US7973042B2 (en) Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors
KR20110034020A (en) Alkyl thiazole carbamate derivatives, their preparation, and their use as FAH enzyme inhibitors
NZ546309A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
JP2022081702A (en) Pyrazole compound
HK1141527A (en) Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
HK1142069A (en) Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof
MXPA06009627A (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION